Tumor-Associated Macrophages: Recent Insights and Therapies

被引:458
作者
Zhou, Jiawei [1 ,2 ,3 ,4 ]
Tang, Ziwei [1 ,2 ,3 ,4 ]
Gao, Siyang [4 ]
Li, Chunyu [4 ]
Feng, Yiting [4 ]
Zhou, Xikun [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China
[3] Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China
[4] Sichuan Univ, State Key Lab Oral Dis, Natl Clin Res Ctr Oral Dis, West China Coll Stomatol,Chinese Acad Med Sci,Res, Chengdu, Peoples R China
关键词
macrophages; tumors; tumor-associated macrophages; immunity; immunity therapy; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER CELLS; EXPRESSION; ACTIVATION; BLOCKADE; PD-1; PHAGOCYTOSIS; METASTASIS; INHIBITION; IL-10;
D O I
10.3389/fonc.2020.00188
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Macrophages, which have functions of engulfing and digesting foreign substances, can clear away harmful matter, including cellular debris and tumor cells. Based on the condition of the internal environment, circulating monocytes give rise to mature macrophages, and when they are recruited into the tumor microenvironment and in suitable conditions, they are converted into tumor-associated macrophages (TAMs). Generally, macrophages grow into two main groups called classically activated macrophages (M1) and alternatively activated macrophages (M2). M2 and a small fraction of M1 cells, also known as TAMs, not only lack the function of phagocytizing tumor cells but also help these tumor cells escape from being killed and help them spread to other tissues and organs. In this review, we introduce several mechanisms by which macrophages play a role in the immune regulation of tumor cells, including both killing factors and promoting effects. Furthermore, the targeted therapy for treating tumors based on macrophages is also referred to in our review. We confirm that further studies of macrophage-focused therapeutic strategies and their use in clinical practice are needed to verify their superior efficacy and potential in cancer treatment.
引用
收藏
页数:13
相关论文
共 86 条
[1]   CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma [J].
Advani, Ranjana ;
Flinn, Ian ;
Popplewell, Leslie ;
Forero, Andres ;
Bartlett, Nancy L. ;
Ghosh, Nilanjan ;
Kline, Justin ;
Roschewski, Mark ;
LaCasce, Ann ;
Collins, Graham P. ;
Thu Tran ;
Lynn, Judith ;
Chen, James Y. ;
Volkmer, Jens-Peter ;
Agoram, Balaji ;
Huang, Jie ;
Majeti, Ravindra ;
Weissman, Irving L. ;
Takimoto, Chris H. ;
Chao, Mark P. ;
Smith, Sonali M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (18) :1711-1721
[2]   SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors [J].
Alvey, Cory M. ;
Spinler, Kyle R. ;
Irianto, Jerome ;
Pfeifer, Charlotte R. ;
Hayes, Brandon ;
Xia, Yuntao ;
Cho, Sangkyun ;
Dingal, P. C. P. Dave ;
Hsu, Jake ;
Smith, Lucas ;
Tewari, Manu ;
Discher, Dennis E. .
CURRENT BIOLOGY, 2017, 27 (14) :2065-+
[3]   critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo [J].
Arnold, Christina E. ;
Whyte, Claire S. ;
Gordon, Peter ;
Barker, Robert N. ;
Rees, Andrew J. ;
Wilson, Heather M. .
IMMUNOLOGY, 2014, 141 (01) :96-110
[4]   Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment [J].
Azizi, Elham ;
Carr, Ambrose J. ;
Plitas, George ;
Cornish, Andrew E. ;
Konopacki, Catherine ;
Prabhakaran, Sandhya ;
Nainys, Juozas ;
Wu, Kenmin ;
Kiseliovas, Vaidotas ;
Setty, Manu ;
Choi, Kristy ;
Fromme, Rachel M. ;
Phuong Dao ;
McKenney, Peter T. ;
Wasti, Ruby C. ;
Kadaveru, Krishna ;
Mazutis, Linas ;
Rudensky, Alexander Y. ;
Pe'er, Dana .
CELL, 2018, 174 (05) :1293-+
[5]   The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ [J].
Banerjee, Sayantan ;
Halder, Kuntal ;
Ghosh, Sweta ;
Bose, Anamika ;
Majumdar, Subrata .
ONCOIMMUNOLOGY, 2015, 4 (03) :1-12
[6]   TLR signaling-mediated differential histone modification at IL-10 and IL-12 promoter region leads to functional impairments in tumor-associated macrophages [J].
Banerjee, Sayantan ;
Halder, Kuntal ;
Bose, Anamika ;
Bhattacharya, Parna ;
Gupta, Gaurav ;
Karmahapatra, Santanu ;
Das, Shibali ;
Chaudhuri, Shubho ;
Bhattacharyya Majumdar, Suchandra ;
Majumdar, Subrata .
CARCINOGENESIS, 2011, 32 (12) :1789-1797
[7]   CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy [J].
Barkal, Amira A. ;
Brewer, Rachel E. ;
Markovic, Maxim ;
Kowarsky, Mark ;
Barkal, Sammy A. ;
Zaro, Balyn W. ;
Krishnan, Venkatesh ;
Hatakeyama, Jason ;
Dorigo, Oliver ;
Barkal, Layla J. ;
Weissman, Irving L. .
NATURE, 2019, 572 (7769) :392-+
[8]   Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy [J].
Barkal, Amira A. ;
Weiskopf, Kipp ;
Kao, Kevin S. ;
Gordon, Sydney R. ;
Rosental, Benyamin ;
Yiu, Ying Y. ;
George, Benson M. ;
Markovic, Maxim ;
Ring, Nan G. ;
Tsai, Jonathan M. ;
McKenna, Kelly M. ;
Ho, Po Yi ;
Cheng, Robin Z. ;
Chen, James Y. ;
Barkal, Layla J. ;
Ring, Aaron M. ;
Weissman, Irving L. ;
Maute, Roy L. .
NATURE IMMUNOLOGY, 2018, 19 (01) :76-+
[9]   Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma [J].
Binenbaum, Yoav ;
Fridman, Eran ;
Yaari, Zvi ;
Milman, Neta ;
Schroeder, Avi ;
Ben David, Gil ;
Shlomi, Tomer ;
Gil, Ziv .
CANCER RESEARCH, 2018, 78 (18) :5287-5299
[10]   Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity [J].
Borghese, Cinzia ;
Cattaruzza, Lara ;
Pivetta, Eliana ;
Normanno, Nicola ;
De Luca, Antonella ;
Mazzucato, Mario ;
Celegato, Marta ;
Colombatti, Alfonso ;
Aldinucci, Donatella .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (05) :1135-1144